Novo Nordisk’s Wegovy bonanza looms large in Denmark

The whirlwind success of weight-loss treatment Wegovy is providing a bonanza not just for its developer, Novo Nordisk, but also for its home country of Denmark. Interviews with Danish economists, analysts, and executives at the Novo Nordisk Foundation which controls Novo highlight the benefits to the economy from jobs to private wealth – but also the potential pitfalls of relying on a single, outsized company. "Danes are exposed to the success of Novo Nordisk, but also the risk – both because it is the most widely held stock in Denmark, and because of the company's impact on our society," Danske Bank investment strategist Lars Skovgaard Andersen said.